Incretin ‐based glucose‐lowering medications and the risk for acute pancreatitis and/or pancreatic cancer risk: Reassuring data from cardio‐vascular outcome trials

Abstract Incretin‐based medications (glucagon‐like peptide‐1 [GLP‐1] receptor agonists and inhibitors of dipeptidyl peptidase‐4 [DPP‐4] are glucose‐lowering drugs approved and introduced after 2006 (1). Although both classes of drugs appeared to be relatively safe based on results from clinical trials and standard animal toxicology studies, epidemiological data (2, 3) and histological findings (4) in genetically modified rodents exposed to such agents have raised concern that pancreatitis and pancreatic cancer may be long‐term risks associated with this therapy.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: RESEARCH LETTER Source Type: research